2017
Geographical differences in survival of dogs with non‐Hodgkin lymphoma treated with a CHOP based chemotherapy protocol
Wilson‐Robles H, Budke C, Miller T, Dervisis N, Novosad A, Wright Z, Thamm D, Vickery K, Burgess K, Childress M, Lori J, Saba C, Rau S, Silver M, Post G, Reeds K, Gillings S, Schleis S, Stein T, Brugmann B, DeRegis C, Smrkovski O, Lawrence J, Laver T. Geographical differences in survival of dogs with non‐Hodgkin lymphoma treated with a CHOP based chemotherapy protocol. Veterinary And Comparative Oncology 2017, 15: 1564-1571. PMID: 28419683, DOI: 10.1111/vco.12302.Peer-Reviewed Original ResearchConceptsProgression-free survivalFree survivalMultivariable Cox regression modelsShorter progression-free survivalSurvival of dogsCox regression modelNon-Hodgkin lymphomaCHOP chemotherapyChemotherapy protocolsReferral institutionMedical recordsUnivariate analysisDoxorubicin dosesCanine lymphomaVeterinary oncologyDoxorubicin treatmentGeographical differencesLymphomaDogsSignificant differencesImmunophenotypeSurvivalRegression modelsGeographic differencesUS regions
2016
Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009–2013
Olmsted G, Farrelly J, Post G, Smith J. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009–2013. Journal Of Feline Medicine And Surgery 2016, 19: 568-575. PMID: 26951557, PMCID: PMC11128809, DOI: 10.1177/1098612x16638118.Peer-Reviewed Original ResearchConceptsOral squamous cell carcinomaSquamous cell carcinomaToceranib phosphateCell carcinomaTreatment modalitiesFeline oral squamous cell carcinomaMetabolic toxicityNon-steroidal anti-inflammatory drugsCurrent treatment optionsFavorable toxicity profileCommon oral tumorAnti-inflammatory drugsMajority of catsAdditional therapyGastrointestinal toxicityGI toxicityMedian doseSurgical excisionTreatment delayPoor prognosisTreatment optionsOral tumorsDose reductionRadiation therapyToxicity profile